Mentari Therapeutics, Inc. (MTRI) P/E Ratio, ROE & Key Statistics
$19.87OTC: MTRIMarket Cap $10.92M
Data as of Nov 16, 2026 (intraday, delayed) · Source: Financial Modeling Prep (methodology)
Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Mentari Therapeutics, Inc. (MTRI), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
0.00
P/B ratioShare price divided by book value per share.
4.60
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-31200.00%
Free cash flow yieldFree cash flow as a percentage of market value.
-195.51%
Profitability
Metric
Value
Return on equityProfit as a percentage of shareholders’ equity.
-1300.00%
Return on assetsProfit as a percentage of total assets.
-433.33%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
1.50
Quick ratioThe same, excluding inventory.
1.00
Cash ratioCash alone against current liabilities.
5.50
Debt to equityTotal borrowings against shareholders’ equity.
0.00
Debt to assetsTotal borrowings against total assets.
0.00
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
−$3.12
Market capitalisationShare price times shares outstanding.
$10.92M
Mentari Therapeutics, Inc. (MTRI) statistics — frequently asked questions
What is Mentari Therapeutics, Inc.'s return on equity?
Mentari Therapeutics, Inc. (MTRI) reports a return on equity of -1300.00%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does Mentari Therapeutics, Inc. carry?
Mentari Therapeutics, Inc. (MTRI) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.